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Abstract 
Background: Assessing the location and frequency of HIV integration sites in latently infected cells can potentially 
inform our understanding of how HIV persists during combination antiretroviral therapy. We developed a novel high 
throughput sequencing method to evaluate HIV integration sites in latently infected cell lines to determine whether 
there was virus replication or clonal expansion in these cell lines observed as multiple integration events at the same 
position.
Results: We modified a previously reported method using random DNA shearing and PCR to allow for high through-
put robotic processing to identify the site and frequency of HIV integration in latently infected cell lines. Latently 
infected cell lines infected with intact virus demonstrated multiple distinct HIV integration sites (28 different sites in 
U1, 110 in ACH-2 and 117 in J1.1 per 150,000 cells). In contrast, cell lines infected with replication-incompetent viruses 
(J-Lat cells) demonstrated single integration sites. Following in vitro passaging of the ACH-2 cell line, we observed 
a significant increase in the frequency of unique HIV integration sites and there were multiple mutations and large 
deletions in the proviral DNA. When the ACH-2 cell line was cultured with the integrase inhibitor raltegravir, there was 
a significant decrease in the number of unique HIV integration sites and a transient increase in the frequency of 2-LTR 
circles consistent with virus replication in these cells.
Conclusion: Cell lines latently infected with intact HIV demonstrated multiple unique HIV integration sites indicating 
that these cell lines are not clonal and in the ACH-2 cell line there was evidence of low level virus replication. These 
findings have implications for the use of latently infected cell lines as models of HIV latency and for the use of these 
cells as standards.
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(http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, 
provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, 
and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/
publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
Background
Despite the success of suppressive combination antiretro-
viral therapy (cART), HIV persists as integrated provirus 
in long lived latently infected cells, typically resting mem-
ory CD4+ T-cells [1, 2]. Latently infected memory CD4+ 
T-cells are rare in individuals on cART, occurring at a 
frequency of 10–100 per million cells [3], and therefore, 
are difficult to study ex  vivo. Multiple in  vitro models 
of HIV latency have been developed including latently 
infected cells lines and primary T-cells [4]. Understand-
ing the location and frequency of HIV integration in the 
host genome in models of HIV latency as well as resting 
CD4+ T-cells from HIV-infected individuals on cART 
can potentially provide insights into the origin of infec-
tion, clonal expansion and potentially the response to 
latency reversing agents [5].
Latently infected cell lines are established following 
infection with either intact, replication-competent virus 
or mutated, replication-defective viruses. Examples 
of cell lines infected with replication competent virus 
include U1, ACH-2 and J1.1 cells [6–9] and with repli-
cation defective virus include J-Lat, where the cell lines 
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are monoclonal and harbour a single integration site [10, 
11]. In CD4+ T-cells from HIV-infected individuals on 
cART, several groups have recently shown a significant 
expansion of latently infected cells with a distinct site 
of integration, consistent with clonal expansion in  vivo 
[5, 12–14]. Understanding whether similar patterns of 
integration occur in in vitro models of HIV latency and 
in patient derived cells is important, if these models are 
to be used to study the establishment, maintenance and 
reversal of latency.
Strategies to determine sites of HIV integra-
tion include sequencing and cloning [15, 16] or bulk 
sequencing [5, 12, 13, 17]. Most bulk sequencing 
approaches use restriction enzymes or random shear-
ing of genomic DNA followed by PCR, using primers 
in the long terminal repeat (LTR) and a linker [5, 12, 
13, 17]. Random shearing leads to different sized PCR 
products. Therefore, if an identical HIV integration site 
is detected but the length of the PCR product is differ-
ent, it is most likely that this HIV integration sites was 
derived from a clonally expanded cell. Another method 
of determining the frequency of HIV integration sites is 
by limiting dilution of genomic DNA based on the esti-
mated copies of HIV integrated DNA followed by loop 
amplification, and sequencing using primers located in 
the LTR [14].
Here, we describe a method to significantly stream-
line the assessment of HIV integration sites using robotic 
processing. Using this method, we evaluated HIV inte-
gration sites in commonly used latently infected cell lines 
and demonstrated that multiple cell lines that are tradi-
tionally used to study latency have evidence of productive 
infection.
Methods
Latently infected cell lines
Cells were obtained from NIH AIDS reagent program 
(Table 1) and were maintained in culture medium (CM) 
(RPMI 1640 medium (Life Technologies) supplemented 
with 10% (v/v) heat inactivated FCS, 100 μg/ml penicillin, 
100 μg/ml streptomycin (Life Technologies) at 37 °C and 
5% CO2. Cells were divided in a ratio of 1:6 or 1:10 twice 
weekly.
Sample collection for integration site analysis
To assess HIV integration sites in a panel of latently 
infected cell lines, all cells were passaged ten times 
in a 1:6 dilution twice weekly. High molecular weight 
genomic DNA (gDNA) was isolated from every other 
passage (i.e. passages 0, 2, 4, 6, 8 and 10) according to 
manufacturer’s protocol (Blood & Cell Culture DNA 
Mini Kit, QIAGEN). Passage zero was before the start of 
culture and sample was obtained from cryovials received 
from the NIH AIDS reagent program. To assess the effi-
ciency of the HIV integration site analysis method, we 
spiked 1.5 µg high molecular weight gDNA from (periph-
eral blood mononuclear cells (PBMC) corresponding to 
approximately 2 × 105 cells) derived from an HIV nega-
tive donor with high molecular weight gDNA from J-Lat 
8.4, J-Lat 15.4 and J-Lat tat-GFP 82 cell line correspond-
ing to a total of 125 cells. To test specificity, we analysed 
1.5 µg gDNA PBMC from an HIV negative donor.
In some experiments ACH-2 cells were cultured in 
CM with and without 1 µM raltegravir (NIH AIDS rea-
gent program). Cells were passaged nine times in a 1:10 
dilution twice weekly and between passage 4 and 12, high 
molecular weight gDNA was isolated according to man-
ufacturer’s protocol (Blood and Cell Culture DNA Mini 
Kit, QIAGEN). HIV integration sites and frequency of 
2-LTR circles were then quantified.
High throughput HIV integration analysis method
High molecular weight DNA corresponding to 1.5E105 
cells was randomly digested for 20  min at 22  °C with 
NEBNext dsDNA fragmentase according to manufac-
turer’s protocol (New England Biolabs, Ipswich, MA) 
to obtain short 200–1200  bp fragments for processing. 
Digested DNA was purified with AMPure XP (Agen-
court Beckman Coulter, Nyon, Switzerland) in a 0.7:1 
ratio, to remove small DNA fragments (<200 bp), buffer 
and fragmentase. The product was end-repaired, A-tailed 
and 10  pmol of linker (Additional file  1: Table  S1) was 
ligated to the product using End-repair, ligation module 
(New England Biolabs) according to the manufacturer’s 
instructions. After purification, restriction digest was 
performed with BglII (New England Biolabs) to remove 
Table 1 Cell lines analysed in this study from NIH AIDS rea-
gent program
ENV envelope, LTR long terminal repeat, tat trans-activator of transcription, GFP 
green fluorescent protein










U1 Yes Mutation in tat 2 [6]
ACH-2 Yes Mutation in tar 1 [7, 8]
J1.1 Yes Wild type 1 [9]
J-Lat 8.4 No Frame shift env 1 [10]
J-Lat 9.2 No Frame shift env 1 [10]
J-Lat 10.6 No Frame shift env 1 [10]
J-Lat 15.4 No Frame shift env 1 [10]
J-Lat tat-GFP 8.2 No LTR-tat-GFP 1 [10, 11]
J-Lat tat-GFP A1 No LTR-tat-GFP 1 [10, 11]
J-Lat tat-GFP H2 No LTR-tat-GFP 1 [10, 11]
J-Lat tat-GFP A72 No LTR-tat-GFP 1 [10, 11]
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the upstream sequence of HIV and prevent sequencing 
of proviral HIV DNA. Purified product was amplified 
using a nested approach. The first round PCR was two 
staged with a first step of LTR dependent linear ampli-
fication with the biotinylated primer LTR1_F (Addi-
tional file  1: Table  S1) for 98  °C for 3  min, followed by 
12 cycles of 98  °C for 1  min, 60  °C for 30  s and 72  °C 
for 1 min, and then 10 min at 72 °C. In the second step, 
the PCR reaction was spiked with 1  µL 10  µM linker 
primer, 1stLink_Primer (Additional file  1: Table  S1) 
that could only anneal when there was LTR dependent 
elongation for increased specificity, and then the same 
cycling conditions for 27 cycles. After purification of the 
PCR product with the AMPure XP (Agencourt Beck-
man Coulter) to remove unbound biotinylated primers, 
biotinylated PCR products were selected by streptavi-
din-coupled Dynabead selection according to the manu-
facturer’s protocol (Thermo Fisher, Malaga, Australia). 
Subsequently, a second round PCR was performed with 
the same cycling conditions for 35 cycles with the mid 
tagged primers LTR2_F and 2ndLink_Primer (Addi-
tional file 1: Table S1). Nested PCR was performed with 
Gotaq hotstart polymerase M5006 chemistry according 
to the manufacturer’s protocol (Promega, Madison, WI).
The purified products were quantitated using Nan-
odrop (Thermo Fisher, Malaga, Australia). Post quan-
tification, up to 12 samples were pooled in equimolar 
amounts and a sequence library was prepared using the 
Kapa Hyper Library prep kit (Kapabiosystems, Wilming-
ton, MS) using 500 ng of pooled product. The library was 
further quantified using qPCR and sequenced by 300 bp 
paired-end sequencing on Illumina MiSeq (Additional 
file  1: Fig.  S1a) at appropriate concentrations. All the 
steps in the HIV integration site analysis methods were 
optimized for robotic processing to minimize contamina-
tion risk and increase throughput.
Data analysis
To determine an HIV integration site, the Miseq reads 
were paired and needed to contain a multiplex-iden-
tifier (MID) sequence on either end of LTR and linker 
based sequence products. These sample read pairs were 
subsequently checked for LTR primer sequence and 
the remaining LTR nucleotide sequence ending on the 
nucleotide sequence CA. No mismatches were allowed 
in this sequence excluding CA (2 in primer sequence, 1 
in LTR end). Furthermore, the linker primer had to be 
present. The sequence of the matched read pairs after the 
LTR or linker were trimmed to 50 base pairs and subse-
quently the trimmed read pairs were grouped according 
to 100% sequence match. Grouped sequences had to have 
≥3 reads to proceed. Well represented sequences were 
used for chromosomal alignment which was determined 
using the Blat-UCSC Genome Browser (GRCH38/hg38). 
An HIV integration site was called if the results had ≥10 
reads, and the frequency was determined by a length dif-
ference of ≥2 nucleotides (Additional file 1: Fig. S2).
HIV DNA sequencing
DNA was extracted from pelleted ACH2 cells using 
QIAamp DNA Blood Mini kit (QIAGEN Inc., Hilden, 
Germany). Two overlapping amplicons spanning the 
HIV near full length genomes were PCR amplified using 
nested PCR with Platinum Taq DNA High Fidelity poly-
merase (Invitrogen, Carlsbad, CA). Each 25  μl reaction 
mixture contained 2.5  μl reaction mix (10×), 0.5  μl of 
each primer (0.5 mM), 0.25 μl Platinum TaqHigh Fidelity 
mix, 1.5  μl MgSO4 (3  mM), 1.25  μl dNTP mix (2  mM) 
and 2.5  μl of template DNA. The two step cycling con-
ditions were 94  °C for 2  min; 15 cycles of 94  °C for 
15  s, 60  °C for 20  s, and 68  °C for 6  min, 20 additional 
cycles of 94  °C for 15  s, 65  °C for 20  s, 68  °C for 6 min 
and finally 68 °C for 10 min. Amplicons were verified by 
agarose gel electrophoresis and quantified using Nan-
odrop. Amplicons were pooled in equimolar amounts. 
500  ng of pooled product was used for preparing the 
indexed libraries for 454FLX and Illumina Miseq plat-
forms. For 454FLX, the library was prepared  using the 
GS FLX Titanium Rapid Library Preparation Kit as per 
manufacturer’s protocol (Roche 454 Life Sciences, Bran-
ford, CT). Library was quantified using the Kapa library 
quantification kit with 454FLX primer premix (Kapa 
Biosystems)  and sequenced on the 454 FLX Titanium 
XL + instrument (454 Life Sciences. Roche Applied Sci-
ences, Branford, CT).  For Illumina sequencing, indexed 
libraries was prepared using the PCR free Kapa Hyper 
Prep kit as per the manufacturer’s protocol (Kapa Bio-
systems). The libraries were quantified using the KAPA 
Library Quantitation qPCR kit with Illumina Primer Pre-
mix (Kapa biosystems) and sequenced on Illumina MiSeq 
using 600 cycle MiSeq reagent kits (version 3). We ana-
lysed transition and transversion mutation additionally to 
insertions and deletion in the envelope gene with these 
two platforms. We called a mutation if the minority read 
count exceeded 1% of the total read count.
2‑LTR circles and CCR5
2-LTR circles were measured as previously described 
[18]. Briefly; 2-LTR circle sequences were amplified by 
nested PCR with the first round PCR conditions includ-
ing a denaturation step of 8 min at 95  °C and 16 cycles 
of amplification (95 °C for 30 s, 55 °C for 30 s, 72 °C for 
1 min), followed by an elongation step of 5 min at 72 °C 
and the second round denaturation step of 10  min at 
95 °C and 40 cycles of amplification (95 °C for 10 s, 60 °C 
for 30 s) followed by an elongation step of 5 min at 72 °C.
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The number of 2-LTR circles were normalized to cel-
lular input by preforming a separate real-time PCR assay 
to quantify the CCR5 coding sequence as previously 
described [19].
Statistical analysis
The numbers of unique integration sites of all passages 
were scored independent of frequency. Differences dur-
ing passaging were assessed using linear regression mod-
els. Differences in 2-LTR circles when the ACH-2 cell line 
was cultured with and without raltegravir was analyzed 
by a one-tailed paired t test. Differences in the decay of 
the number of ACH-2 integration sites with and with-
out raltegravir were determined by regression analysis. 
Differences were considered statistically significant at 
p < 0.05. Gene ontology analysis was performed using the 
GEne SeT Analysis Toolkit [20]. Differences in ontology 
were analysed by Chi square test. All statistical analysis 
was performed using GraphPad Prism 6 and STATA.
Results
Development of a novel high throughput assay to study 
HIV integration
We assessed the efficiency of a novel high throughput 
method to study HIV integration using a mix of uninfected 
(Jurkat and PBMC from HIV-uninfected donors) and 
infected cell lines (J-Lat 8.4, J-Lat 15.4 and J-Lat tat-GFP 
82). We detected 24–30 of 125 (19–24%) integration sites 
in a background of 1.5  µg gDNA from PBMCs from an 
HIV negative donor (n = 3). To test the specificity of our 
assay, we assessed HIV integration sites in 1.5 µg of gDNA 
derived from PBMCs from an HIV negative donor and 
no HIV integration sites were detected (data not shown, 
n  =  3). We included several modifications to a recently 
published method [12] (Additional file 1: Fig. S1b), but the 
main adaptation that improved throughput was enzymatic 
random digestion with NEBNext dsDNA fragmentase, 
based on previous reports showing similar efficacy in 
DNA fragmentation to sonication [21]. After fragmenta-
tion, the use of nd-repair ligation module (New England 
Biolabs) which is a single step allowed ligation without 
product clean-up and therefore reduced the number of 
steps considerably. Furthermore, in our protocol we omit-
ted linker ligation. By not digesting the linker, the second 
round nested PCR could also be performed with barcoded 
linker primers. Therefore the reverse reads were barcoded 
and sample specific. These changes enabled the whole pro-
cedure to be performed in a 96 well format allowing for 
up to 96 samples to be analysed in 16  h, which was run 
entirely on a robotic platform, making sample processing 
consistent. Only sample preparation was performed man-
ually which meant that on average integration site analysis 
of 6-8 samples could be completed in 24 h.
Diverse integration sites in latently infected cell lines 
infected with intact replication‑competent viruses
We next analysed HIV integration sites in established 
latently infected cell lines generated using intact replica-
tion-competent viruses or defective, replication-incom-
petent viruses. Cell lines reported to be infected with 
a replication-competent virus demonstrated multiple 
unique integration sites (number of unique integrations 
sites per 150,000 cells was 24–30, 89–124 and 123 in U1 
(n = 2), ACH-2 (n = 2) and J1.1 cells (n = 1) respectively). 
Whereas the number of total integration sites detected 
in 150,000 cells was 667–754, 589–649 and 577 in U1 
(n = 2), ACH-2 (n = 2) and J1.1 cells (n = 1) respectively). 
In contrast, all cell lines infected with a replication-incom-
petent virus (i.e. J-Lat cell lines) had a single unique inte-
gration site. This observation raised the possibility that 
there was ongoing infection of uninfected cells during cell 
passaging. In the ACH-2 cell line, the number of unique 
integration sites significantly increased over time in cul-
ture (p = 0.02), whereas it remained stable in J1.1 and U1 
(Fig. 1). In contrast, all HIV integration sites in the J-Lat 
cell lines remained stable over time and were restricted to 
a single unique site (Table 2) (with a median of 388 (range 
265–413) of total integration sites detected per 150,000 
cells). The HIV integration sites in J-Lat cells 8.4, 9.2 and 
15.4 were detected as previously reported [22].
We also analysed the orientation of integrated HIV 
and if there were differences in integration within genes 
(intron, exon) or in nongenic regions in the U1, ACH-2 
and J1.1 cell lines from passage zero and passage ten. We 
Fig. 1 Change in frequency of HIV integration sites following pas-
saging of cell lines infected with replication-competent HIV. The 
frequency of unique integration sites per 150,000 cells is shown 
following passaging of the U1 (green), ACH2 (blue) and J1.1 (red) cell 
lines. Linear regression was used to determine if the change was 
statistically significant
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found that most integration sites were within genes and 
specifically introns, and there was no preference in orien-
tation of HIV integration and this did not change follow-
ing passaging (Fig. 2).
Identity of genes where HIV integrates in latently infected 
cell lines
We next analysed the specific gene locations of HIV 
integration sites that were frequently detected during 
in  vitro passaging. In the U1 cell line, we detected two 
major sites with high frequency. One site was in chromo-
some 2 in the AC079807.4 gene with the 3′ LTR junction 
at nucleotide position 48,177,527 whereas the other site 
was found in chromosome X in a functionally unknown 
region. Interestingly, an additional site was continuously 
detected in chromosome 19, in the ubiquitin-like modi-
fier activating enzyme 2 (UBA2) gene, in about 4 percent 
of events that were detected (Table 2).
In the ACH-2 cell line, the major HIV integration site 
was detected in chromosome 7 in the cytosolic 5′-nucle-
otidase 3A (NT5C3A) gene as previously reported [17, 
23]. We also detected an additional integration site in 
chromosome 9 which was always detected in high fre-
quency in the solute carrier family 25 antisense RNA 
(SLC25A25-AS) noncoding RNA gene as recently 
reported [17]. Additionally, we detected two sites with 
multiple integration events intermittently, one in chro-
mosome 2 in the ethanolaminephosphotransferase 1 
(EPT1) gene, the other in chromosome 17 in the nuclear 
protein localization 4 (NPLOC4) gene (Table 2).
Although previous reports have described a single copy 
of integrated HIV per cell in the J1.1 cells [9], we detected 
two major integration sites in 150,000 cells with equal 
frequency in passage zero before start of cell culture. One 
was detected in chromosome 11 in the deformed epider-
mal autoregulatory factor 1 (DEAF1) gene and the other 
in chromosome 12 in the chromobox homolog 5 (CBX5) 
gene (Table 2). During the ten passages, the HIV integra-
tion site in all the J-Lat cell lines remained single and sta-
ble and the identified integration sites represented 100% 
of the total events detected (Table 2).
We analysed the genes where HIV integrated following 
passage zero and passage ten for the U1, ACH-2 and J1.1 
cell lines. We observed that with passaging, the number 
of HIV integration sites in genes decreased in the U1 cell 
line (Fig. 3a), but increased in ACH-2 (Fig. 3b) and J1.1 
(Fig. 3c) cell lines. The proportion of integration sites in 
genes associated with cellular proliferation was approxi-
mately 10% and did not significantly differ between the 
passages in all cells.
Table 2 HIV integration sites in latently infected cell lines
a The particular chromosome where the HIV integration site is located
b The first human genome nucleotide following 3′-end LTR
c The gene where HIV is integrated
d Transcription direction of the gene
e Transcription direction of HIV
f Percentage of events where the particular HIV integration site was detected in all passages
Cell line Replication com‑
petent virus
Chromosomea Positionb Genec Gene orientationd HIV orientatione Percentage 
of eventsf
U1 Yes 2 48,177,527 AC079807.4 − + ≈38%
X 38,811,467 − ≈55%
19 34,452,847 UBA2 + + ≈3%
ACH-2 Yes 7 33,019,791 NT5C3A − − ≈37%
9 128,111,651 SLC25A25-AS − − ≈13%
2 26,386,668 EPT1 + + ≈2%
17 81,558,479 NPLOC4 + − ≈1%
J1.1 Yes 11 685,243 DEAF1 − − ≈41%
12 54,257,973 CBX5 − − ≈38%
J-Lat 8.4 No 1 7,946,384 FUBP1 − − 100%
J-Lat 9.2 No 19 4,381,104 PPP5C + + 100%
J-Lat 10.6 No 9 136,468,579 SEC16A − + 100%
J-Lat 15.4 No 19 34,441,293 UBA2 + + 100%
J-Lat tat-GFP 8.2 No 10 39,936,068 + 100%
J-Lat tat-GFP A1 No X 34,073,326 − 100%
J-Lat tat-GFP H2 No 2 171,821,429 SLC25A12 − + 100%
J-Lat tat-GFP A72 No X 45,038,538 KDM6A + − 100%
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We then compared the integration sites in the cell lines 
with those found in CD4+ T-cells from HIV-infected 
individuals on cART, which have been previously 
reported in the literature [5, 12–14, 24]. The number 
of integration sites we detected in the U1, ACH-2 and 
J1.1 cell lines overlapped 22, 33 and 35% respectively 
when compared to HIV integration sites found in cells 
from HIV-infected individuals on ART. This suggests 
Fig. 2 Site, frequency and nature of HIV integration sites in latently infected cells lines. A logarithmic depiction of HIV integration sites per million 
bases prior to passaging is shown for a U1, b ACH-2, and c J1.1. Chromosome numbers are labelled on the perimeter of the outer circle. The outer 
circle represents the different chromosomes with gene dense regions in grey bars representing different genes and in blue the centromere. The 
chromosomes are scaled to 50 million basepair bins. The integration sites for each chromosome are cumulative per million bases of the chromo-
some. The integration sites are shown as a coloured lines pointing to the centre of the circle. The frequency is represented in a logarithmic scale. 
The inner multi-colored solid circle summarises the nature of all the integration sites as genic (same or opposite orientation), non-genic, exonic and 
intronic. The specific site of integration is shown for each chromosome with the first ring showing integration within a gene with the same orienta-
tion compared to the host gene [genic (same orientation)] in red. The second ring shows HIV integration sites and within a gene with the opposite 
orientation compared to the host gene [genic (opposite orientation)] in blue. The third ring shows HIV integration sites not in a gene (non-genic) in 
green. In the fourth ring HIV integration sites in an exon (exonic) are in purple. In the fifth ring HIV integration sites in an intron (intronic) are in black
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Fig. 3 Gene ontology analysis of latently infected cell lines. The gene ontology of HIV integration sites detected in the a U1, b ACH-2 and c J1.1 
cell lines using Gene SeT Analysis Toolkit is shown as the number of genes in a distinct family for passage 0 (blue bar) and passage 10 (red bar). The 
proportion of HIV integration sites detected more than once (blue, multiple integration events) or on one occasion (green, single integration event) 
in the d U1, e ACH-2 (3e) and f J1.1 cell lines at passage 0 (p0) and 10 (p10) is shown as a pie chart
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that many sites of HIV integration identified in latently 
infected cell lines were not identified in cells from HIV-
infected individuals on ART.
Multiple identical integration sites in latently infected cell 
lines
We analysed the percentage of identical integration 
events compared to total integration sites per cell line. 
Identical integration sites were defined as two or more 
integration events. In the U1 cell line, which contains 
an intact virus, most integration sites were identical 
and detected multiple times (97% of all integration sites 
detected were identical at passage 0) and did not change 
during passage (98% at passage 10) (Fig.  3d). In the 
ACH-2 cell line, we observed a significant decrease in the 
percentage identical integration events (from 80% at pas-
sage 0–51% at passage 10, p < 0.001) (Fig. 3e). In the J1.1 
cell line, the percentage of identical integration events 
did not significantly differ during passage (80% at passage 
0, 78% at passage 10) (Fig. 3f ).
Change in integration sites over time in culture is 
consistent with residual virus replication in latently 
infected ACH‑2 cell line
To determine if the observed effects in the ACH-2 cell 
line were due to ongoing virus replication, we sequenced 
the integrated provirus from the ACH-2 cell line from 
passage 1 with two deep sequencing methods and ana-
lysed the envelope gene and demonstrated multiple 
transition and transversion mutations, insertions and 
deletions with 454 sequencing. Moreover with illumina 
Miseq sequencing we observed multiple transition (50) 
and transversion [36] mutations, insertions [8] and dele-
tions [5] With 70–80% of the mutations,insertions and 
deletions detected in the Miseq data overlapping with the 
mutations found by 454 sequencing.
Subsequently, we analysed the frequency of 2-LTR cir-
cles in the ACH-2 cell line cultured with and without 
1 µM raltegravir. Surprisingly, in the ACH-2 cell line, we 
detected 2-LTR circles in cells collected from each pas-
sage. We detected significantly more 2-LTR circles per 
million cells in the first three passages with raltegra-
vir compared to without raltegravir (p =  0.04, p =  0.02 
and p  <  0.01 for the first three passages compared to 
baseline). As expected, 2-LTR circles were detected in 
the positive control of the CEM cell line spiked with the 
2-LTR plasmid while 2-LTR circles were not detected in 
the uninfected CEM cell line, in the CEM cell line spiked 
with pNL4-3 or the J-Lat 15.4 and 10.6 cell lines (Fig. 4a). 
We observed a decrease in the number of unique integra-
tion sites over time following twice weekly passage and 
a faster decay in the number of HIV integration sites in 
the ACH-2 cell line cultured with raltegravir compared 
to without raltegravir (half-life of number of integration 
sites per passage was 1.81 versus 2.96 passage respec-
tively) although the difference was not statistically sig-
nificant (p  =  0.57) (Fig.  4b). Moreover, we observed a 
consolidation around the reported dominant integration 
site in chromosome seven from 32% in passage four to 
74% in passage 12.
Discussion
In this study, we developed a high-throughput assay to 
analyse HIV integration sites using enzymatic random 
fragmentation. Our assay was specific and was able to 
detect 25% of the HIV integration sites using infected 
cell lines (J-Lats) in a background of human gDNA. In 
cell lines infected with replication-incompetent viruses, 
we observed single integration sites. In contrast, in cell 
lines infected with replication-competent viruses, we 
demonstrated multiple unique HIV integration sites and 
in the ACH-2 cell line, the diversity of integration sites 
increased over time in culture and reduced in the pres-
ence of the antiretroviral drug raltegravir. Therefore, 
these latently infected cell lines were not clonal and the 
findings were consistent with residual virus replication.
The U1 monocytic cell line was cloned from a popula-
tion of chronically HIV-1 infected U937 cells and is one 
of the most-studied cell lines for HIV latency [7]. It has 
been reported that U1 cells contain two copies of inte-
grated HIV DNA [7] and latency is maintained by muta-
tions in Tat with one Tat containing a point mutation, 
H13L, and the other lacking the ATG initiation codon 
[25]. Our analysis demonstrated that the U1 cell line con-
tains multiple distinct HIV integration sites that declined 
with passaging.
J1.1 cells are latently HIV infected cell line cloned 
by limiting dilution from HIV-infected Jurkat cells. 
Although, J1.1 cells are infected with wild type HIVLAV, 
the HIV-infected T-cell clone is defective in IL-2 produc-
tion and Ca2+ mobilization after CD3 stimulation [9]. 
Furthermore, J1.1 cells are reported to be infected with 
a single integrated copy per cell [9]. Interestingly, we 
detected multiple HIV integration sites and identified 
two major integration sites in equal frequency. Why there 
is preferential expansion or persistence of these specific 
integration sites is unclear.
The ACH-2 cell line was established by infection of the 
acute lymphoblastic leukemic T-cell line A3.01 with HIV-
LAI. Cells that survived were cloned resulting in a cell line 
that has been reported to contain a single integrated copy 
of HIV [6, 8]. The major HIV insertion site has been iden-
tified in chromosome 7 [23]. In addition, HIV latency is 
established by a point mutation in TAR (C37T), whereby 
this mutation impairs the response of the LTR to Tat [26]. 
Low level transcription of multiply spliced transcripts 
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persist in ACH-2 cells in the absence of stimulation [27], 
and here, we show that ACH-2 cells harbour multiple 
integration sites in addition to the major site in chromo-
some 7, as recently demonstrated by others [17].
Here, we present multiple lines of evidence consistent 
with residual virus replication in, ACH-2 cell line, and 
evidence suggestive for multiple rounds of replication 
occurring in the U1 and J1.1 cells. The evidence included 
diversity of integration sites in all three cell lines that was 
stable or increasing study directly links several lines of 
evidence demonstrating residual viral over time, and in 
the ACH-2 cell line, an increase in diversity during pas-
sage, numerous mutations in the proviral DNA and an 
increase in 2-LTR circles in the presence of raltegravir. 
Other groups have demonstrated viral production in the 
latently infected cell lines, U1, ACH-2 and J1.1 cells dem-
onstrating continuous expression of viral RNA [28] and 
detection of 2-LTR circles in the ACH-2 cell line [29]. 
Our results are also consistent with the observed increase 
in integration sites in the HIV infected cell line H61-D 
during culture [30]. Olivares et  al. demonstrated that 
during prolonged culture of these cells up to 100 pas-
sages, integration sites were detected in addition to the 
two sites found at passage zero [30].
Recently, Sunshine et  al. [17] hypothesised that the 
presence of infrequent integration sites in the ACH-2 
cell line indicated low-level viral replication. Our study 
presents several lines of evidence demonstrating residual 
viral replication in the latently infected cell line ACH-
2. Additionally, our study is the first to suggest ongoing 
low level replication in othercell lines infected with rep-
lication-competent viruses commonly used to study HIV 
latency. It is important to note that there is no perfect 
model to study HIV latency in  vitro. Latently infected 
cell lines remain valuable in the assessment of latency or 
in activation studies using latency reversing agents. The 
advantages of latently infected cell lines include a high 
frequency of infected cells, the capacity to repeat experi-
ments reproducibly and the ability to answer specific 
mechanistic questions that often isn’t possible in primary 
cells.
It is possible that in our study, we increased the chance 
of cell-to-cell transmission of HIV by passaging cells at 
low dilution, which would allow for cell clumping. It has 
been previously demonstrated that cell-to-cell trans-
mission increases with higher cell density [31, 32]. The 
degree of cell clumping could therefore have an impact 
on the level of residual virus replication in this cell line. 
Interestingly, the ACH-2 cell line is reported to not 
express CD4 on the cell surface, although transcription of 
CD4 can be induced [33]. Similarly, the H61-D cell line 
that demonstrated an increase in integration sites dur-
ing culture did not express CD4 at the cell surface [30]. 
Cell-to-cell transmission can occur through a non-CD4 
dependent process [34, 35] or CD4 could be expressed at 
low levels in the virological synapse.
Similar to other studies, we did not identify a high fre-
quency of the same genes harbouring HIV integration in 
the latently infected cell lines that have been described 
in CD4+ T-cells from HIV-infected individuals on cART 
Fig. 4 The effect of raltegravir on integration sites and 2-LTR circles using the ACH-2 cell line. The ACH2 cell line was passaged multiple times in the 
presence (red) and absence (blue) of raltegravir and a the frequency of 2-LTR circles per million cells and b number of unique integration sites were 
quantified. Positive controls included CEM cells spiked with 2-LTR circles; negative controls were CEM cells, CEM cells spiked with pNL4-3, J-Lat 10.6 
and J-Lat15.4. *p = 0.018 and 0.02, **p = 0.004
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[5, 12–14, 24]. HIV integration in BACH2 and MKL2 [5, 
14], although commonly found in patient derived cells 
were not detected in all the different cell lines. It has 
been suggested that the selective pressure for expansion 
of HIV integration sites into genes associated with cell 
proliferation is absent, since these cell lines have been 
previously immortalized. However, the proportion of 
HIV integration sites in genes associated with cell prolif-
eration was similar in the U1, ACH-2 and J1.1 cell lines 
and in the CD4+ T-cells from HIV-infected individuals 
on cART [5, 14]. Similar findings were recently demon-
strated also using the ACH-2 cell line as well as a primary 
T-cell latency model [17]. Given that the same orienta-
tion of HIV integration relative to the host gene increases 
transcriptional efficiency and latency [36], this might 
potentially explain the higher observed basal HIV reverse 
transcriptase activity in ACH-2 compared to the U1 cell 
line [37]. There were several limitations in our study. First, 
we only report HIV integration sites in latently infected 
cell lines. However, others have compared cell lines to 
primary cell models, and observed similar patterns of 
HIV integration with respect to increased integration in 
intronic regions and no specificity for HIV integration ori-
entation [15, 38, 39]. In addition, there was some overlap 
in the sites of integration in the cell lines and published 
work on cells from HIV-infected individuals on cART [5, 
12, 13, 24]. Second, we were not able to definitely dem-
onstrate if these cells harboured multiple HIV integration 
sites per cell or whether these cell lines contained multiple 
cells with different HIV integration sites. We suspect that 
multiple integration sites per cell, in cell lines and in vivo 
is rare but can occur [30, 40–42]. Moreover, it seems 
unlikely that a new integration event in a cell line is asso-
ciated with the loss of the dominant integration site.
Conclusions
We present a specific and efficient new method to ana-
lyse the location and frequency of HIV integration sites 
suitable for high throughput processing. Using HIV 
latently infected cell lines we demonstrated that latently 
infected cell lines that are infected with a replication-
competent HIV had multiple HIV integration sites, and 
that this was likely due to low level replication. These 
findings have implications for the use of some latently 
infected cell lines as models for HIV latency whereas they 
are not truly latent and one must take into account that 
some cells might have a different number of integrated 
proviruses per cell than previously thought when one 
uses these cells for standardization of assays.
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